

February 28, 2019

**Tianjin Tanabe and Servier Tianjin
join hands to promote TENELIA® in China**

Tianjin Tanabe Seiyaku Co., Ltd. (hereinafter, Tianjin Tanabe; Head Office: Tianjin, China) and Servier Pharma (Tianjin) (Servier Tianjin; Head Office: Tianjin, China) have today signed an exclusive strategic agreement to promote the type 2 diabetes treatment drug TENELIA® (Teneligliptin) in mainland China. Tianjin Tanabe is a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC; Head Office: Osaka, Japan; President & Representative Director, CEO: Masayuki Mitsuka), and Servier Tianjin is a member of Les Laboratoires Servier Group (Servier; Head Office: Paris, France; President: Olivier LAUREAU). TENELIA® was developed by MTPC.

China has about 120 million people with diabetes* which is the world's largest populations of patients with type 2 diabetes. China includes nearly 30% of the worldwide total number of people with diabetes, and the number of people with diabetes is expected to continue to increase. The collaboration with Servier Tianjin, which has approximately 700 MRs in China specializing in diabetes and has a track in sales extending over 40 years, is expected to contribute to the rapid market penetration of TENELIA® and to the maximization of its product value.

TENELIA® is a DPP-4 inhibitor created by MTPC and is the first drug of its kind to originate from Japan. TENELIA® suppresses glucagon release and increases insulin release, subsequently lowering blood-glucose levels by selectively inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates glucagon-like peptide-1 (GLP-1), a hormone excreted from the gastrointestinal tract in response to food ingestion. TENELIA®, with its potent and sustained action, has made it highly effective in lowering each of the blood glucose postprandial levels, as well as fasting blood glucose levels, with once-a-day administration. MTPC has completed the phase 3 clinical studies in China.

China, which is the second largest pharmaceuticals market in the world, is an important market for both MTPC and Servier. Working together, the two companies aim to attain better glycemic control for patients in China by providing a new option for the treatment of diabetes.

*IDF : International Diabetes Federation

**Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

Investor contacts: TEL:+81 6 6205 5110

<Reference>

About Tianjin Tanabe Seiyaku Co., Ltd.

Tianjin Tanabe Seiyaku Co., Ltd. was founded in Tianjin, China, in 1993 through joint financing from Tianjin Lisheng Pharmaceutical Co., Ltd. and MTPC. The company is engaged in the manufacture and sales of pharmaceuticals in China. As a core company of the MTPC group in China, the company seeks to contribute to medical needs in China through the manufacture and sales of high quality pharmaceuticals with the MTPC brand, particularly cardiovascular drugs, gastrointestinal drugs, and anti-allergic agents for patients in China.

About Servier Tianjin

Servier is an international pharmaceutical company governed by a nonprofit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25 percent of its turnover (excluding generic drugs) in research and development and uses all of its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, neuropsychiatric diseases, cancer and diabetes. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com